Pregled bibliografske jedinice broj: 549372
Efficacy and safety of colistin in the treatment of infections caused by multidrug- resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis.
Efficacy and safety of colistin in the treatment of infections caused by multidrug- resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. // Internal medicine, 50 (2011), 9; 1009-1013 doi:10.2169/internalmedicine.50.4270 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 549372 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Efficacy and safety of colistin in the treatment of infections caused by multidrug- resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis.
Autori
Duraković, Nadira ; Radojčić, Vedran ; Boban, Ana ; Mrsić, Mirando ; Sertić, Dubravka ; Serventi-Seiwerth, Ranka ; Nemet, Damir ; Labar, Boris
Izvornik
Internal medicine (0918-2918) 50
(2011), 9;
1009-1013
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
colistin ; MDR bacteria ; neutropenia ; neutropenic fever
Sažetak
A rise in infections with multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is a significant contributor to increased morbidity and mortality of patients with hematologic malignancies. The aim of this study was to determine the efficacy and safety of colistin (colistimethate sodium) in the treatment of serious infections caused by MDR-PA in these patients. A matched pair analysis of renal function, toxicities, and outcome of 26 patients receiving colistin and control subjects was done. All patients had clinical signs of sepsis ; P. aeruginosa was isolated from blood in 69% of patients in colistin group and 84% in control group. Patients treated with colistin received 3 million units every 8 hours for a median duration of 13 days. Additionally, patients re- ceived at least two additional antimicrobial or antifungal drugs. Resolution of infection was achieved in twenty patients (76.9%) receiving colistin and in 17 (65.4%) control subjects. Mortality rate was 11% in both groups. There was no statistically significant differ- ence in the level of serum creatinine, creatinine clearance, or potassium levels before and after treatment between groups. Only one patient receiving colistin developed de novo renal failure and one displayed transient neurologic toxicity. Our results suggest that in patients with hematologic malignancies, colistin is effective in treat- ing severe infections caused by MDR- PA while maintaining an acceptable toxicity profile. Prospective ran- domized studies comparing efficacy and safety of colistin with those of other antipseudomonal drugs are needed.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081872-2061 - LIMFOPROLIFERATIVNE BOLESTI I TRANSPLANTACIJA KRVOTVORNIH MATIČNIH STANICA (Nemet, Damir, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Sveučilište Libertas
Profili:
Mirando Mrsić
(autor)
Dubravka Sertić
(autor)
Ana Boban
(autor)
Vedran Radojčić
(autor)
Boris Labar
(autor)
Ranka Serventi-Seiwerth
(autor)
Damir Nemet
(autor)
Nadira Duraković
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE